ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Donepezil

Also written as “Donepezil Hydrochloride”, “E2020” and “Donepezil TDS”.

Its studies are mostly in Alzheimer Disease · Down Syndrome · Lewy Body Disease · Cognitive Dysfunction · Dementia, led by 14 companies.

Drug pageDonepezil: every studyMany companies study it; this page follows only the 79 they lead. All 184 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 12, 200579 company-led studies, 1 open or runningNext primary completion: May 6, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai391 open or runningphase 4since Sep 12, 2005Nov 9, 2004May 6, 2030phase 1 · NCT07768592
Pfizerits history only70 open or runningphase 4since Sep 9, 2005Sep 8, 2005none ahead
Coriumits history only60 open or runningphase 1since Nov 13, 2016Nov 13, 2016none ahead
Merckits history only50 open or runningphase 2since Feb 14, 2014Oct 21, 2008none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 3, 2012Jan 3, 2012none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Dec 14, 2010Dec 14, 2010none ahead
AstraZenecaits history only30 open or runningphase 1since Jul 9, 2008Jul 9, 2008none ahead
Icure Pharmaceuticalits history only30 open or runningphase 3since Jun 22, 2017May 15, 2013none ahead
GlaxoSmithKlineits history only20 open or runningphase 2since Jun 30, 2006Jun 30, 2006none ahead
Sun Pharmaceutical Industriesits history only20 open or runningphase 1since Jan 11, 2011Jan 11, 2011none ahead

Also a collaborator on its studies: PT Equilab International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eisai only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Nov 9, 2004.

  1. May 14, 2009Phase 4 study in Cognitive DysfunctionNCT00934375 · 145 enrolled · United States
  2. Feb 1, 2010Phase 4 study in Kidney Failure, ChronicNCT01063556 · 6 enrolled · Japan
  3. Jan 12, 2011Phase 2 study in Alzheimer DiseaseNCT01276353 · 45 enrolled · Japan
  4. Jan 14, 2011Phase 3 study in Lewy Body DiseaseNCT01278407 · 142 enrolled · Japan
  5. Jul 26, 2011Phase 3 study in Alzheimer DiseaseNCT01404169 · 260 enrolled · China
  6. Jan 6, 20122 phase 1 studies in Healthy AdultNCT01506752, NCT01506739
  7. Feb 21, 2012Phase 3 study in Alzheimer DiseaseNCT01539031 · 351 enrolled · Japan
  8. Apr 25, 2013Phase 1 study in Healthy Elderly MaleNCT01843556 · 48 enrolled · Japan
  9. Jan 23, 2014Phase 1 study in Healthy SubjectsNCT02055703 · 195 enrolled · United States
  10. Mar 19, 2014Phase 2 study in Down SyndromeNCT02094053 · 36 enrolled · Japan
  11. Mar 24, 2014Phase 4 study in Alzheimer DiseaseNCT02097056 · 171 enrolled · Korea, Republic of
  12. Jan 19, 2015Phase 4 study in Lewy Body DiseaseNCT02345213 · 160 enrolled · Japan
  13. Jan 18, 2016Phase 4 study in Dementia Associated With Cerebrovascular DiseaseNCT02660983 · 302 enrolled · Korea, Republic of
  14. Aug 12, 2026Phase 1 study in Alzheimer DiseaseNCT07768592 · 32 planned

Ahead

  1. May 6, 2030Primary completion: phase 1 study in Alzheimer DiseaseNCT07768592

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
huperzine Arulewanbangde-pharmaceutical-group-co-ltdphase 47
benzgalantamine gluconaterulealpha-cognition-incphase 41
Z 338ruleZeria Pharmaceuticalphase 312

Studies

All 39 Eisai leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07768592Alzheimer Disease1Not yet recruitingMay 6, 203032
NCT02660983Dementia Associated With Cerebrovascular Disease · Korea, Republic of4CompletedJul 13, 2018302
NCT02345213Lewy Body Disease · Japan4CompletedMay 15, 2017160
NCT02097056Alzheimer Disease · Korea, Republic of4CompletedMay 2015171
NCT02094053Down Syndrome · Japan2CompletedSep 16, 201636
NCT02055703Healthy Subjects · United States1CompletedApr 2014195
NCT01843556Healthy Elderly Male · Japan1CompletedApr 201348
NCT01539031Alzheimer Disease · Japan3CompletedJan 2015351
NCT01506752Healthy Adult · Japan1CompletedSep 201120
NCT01506739Healthy Adult · Japan1CompletedMay 201112
NCT01404169Alzheimer Disease · China3CompletedJul 2014260
NCT01278407Lewy Body Disease · Japan3CompletedMar 2013142
NCT01276353Alzheimer Disease · Japan2CompletedApr 201245
NCT01063556Kidney Failure, Chronic · Japan4CompletedMar 20106
NCT00934375Cognitive Dysfunction · United States4CompletedSep 2007145
NCT01146509Migraine Disorders · United States2CompletedApr 200489
NCT00754052Down Syndrome · United States3TerminatedNov 20088
NCT00754013Down Syndrome · United States3TerminatedOct 20089
NCT00688376Neoplasms · United States, Argentina, Australia and more3CompletedMay 26, 200972
NCT00675025Down Syndrome · United States2TerminatedNov 13, 2008117
NCT00711204Alzheimer Disease · United States4WithdrawnJun 20090
NCT00598650Lewy Body Disease2CompletedMar 2011160
NCT00571064Mild to Severe Alzheimer's Disease · United States4CompletedDec 200897
NCT00570128Down Syndrome · United States2CompletedSep 5, 2008129
NCT00566501Alzheimer Disease · United States3CompletedApr 1, 2010915
NCT00543855Lewy Body Disease · Japan2CompletedFeb 2010167
NCT00477659Alzheimer Disease · United States4CompletedAug 15, 200814
NCT00478205Alzheimer Disease · United States3CompletedJun 20091,467
NCT00381381Alzheimer Disease · Korea, Republic of4CompletedAug 31, 2008199
NCT00293176Memory Disorders · United States4CompletedMar 2007821
NCT00230568Alzheimer Disease · United States4CompletedApr 2007100
NCT00165815Dementia With Parkinson's Disease · Germany, Ireland3Completed
NCT00165763Dementia, Vascular · Philippines4CompletedSep 200936
NCT00165750Alzheimer Disease · Korea, Republic of4TerminatedAug 200840
NCT00165737Dementia, Vascular · United States3CompletedAug 2005974
NCT00165724Alzheimer Disease · Korea, Republic of4CompletedJul 31, 2006114
NCT00165659Alzheimer Disease · Japan2CompletedMay 2005
NCT00103948Cognitive Dysfunction · United States, Australia, Spain2CompletedOct 2006165
NCT00096473Alzheimer Disease · United States, Australia, Canada and more3CompletedJun 2005229

How it is read

Names in the registry

  • “Donepezil”, 26 entries
  • “Donepezil Hydrochloride”, 14 entries
  • “E2020”, 7 entries
  • “Donepezil TDS”, 5 entries
  • “Donepezil hydrochloride”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.